Compare Apple Inc (AAPL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Incyte Corporation — how do they compare? Apple Inc trades at $304.48 (market cap $4.45T), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Apple Inc is far larger — about 181.3× Incyte Corporation's market cap, and Apple Inc pays a 0.35% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AAPL | INCY | |
|---|---|---|
Market Cap | $4.45T | $24.54B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $129.93 |
52-Week Low | $224.90 | $81.61 |
Enterprise Value | $4.47T | $20.04B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and support near $306. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.98. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Recent news highlights AI potential through a partnership with Alphabet's Gemini, but store closures and union disputes pose headwinds.
Outlook remains positive with a consensus price target of $337.63, implying 9.5% upside, supported by robust cash flow and a 63.6% buy rating from analysts. Risks include weaker iPhone sales, regulatory fines, and competitive pressures in AI. The stock offers growth potential but requires monitoring of execution risks and macroeconomic trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
